BCL2L11

Across TCGA pan-cancer cohorts, BCL2L11 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of BCL2L11’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where BCL2L11 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types BCL2L11 is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.

LUAD, HNSC, and LSCC are the cancer types where BCL2L11 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BCL2L11 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	II,III,IV	−0.504	<.001	8	view →
HNSC	All	IV	+0.474	.001	8	view →
LSCC	Female	All	+0.581	<.001	7	view →
PDAC	Male	All	+0.490	.010	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

BCL2L11–LUAD

Open the LUAD breakdown →